See the DrugPatentWatch profile for Reclast
What is Reclast, and what is it used for in osteoporosis?
Reclast is the brand name for zoledronic acid, a bisphosphonate given by intravenous (IV) infusion. In osteoporosis, it’s used to reduce the risk of fractures in appropriate patients, including for people at higher risk of fracture due to low bone density.
How is Reclast given for osteoporosis?
Reclast is typically administered as an IV infusion once per year for osteoporosis indications. The exact regimen depends on the patient’s osteoporosis diagnosis and risk profile, and clinicians may also adjust the plan based on kidney function and other factors.
Who should be careful or avoid Reclast?
Because zoledronic acid is eliminated through the kidneys, people with significant kidney impairment are generally the main group that requires extra caution or may not be candidates, depending on local prescribing guidance. Also, clinicians typically check bone health and ensure patients have adequate calcium and vitamin D before dosing to reduce the risk of low calcium after infusion.
What side effects are patients most likely to ask about?
Commonly reported side effects for IV zoledronic acid products include short-term flu-like symptoms after the infusion (fever, aches), and GI effects in some patients. Clinicians also monitor for effects that matter in osteoporosis care, such as low calcium after treatment, and they assess risk factors related to rare but serious bone/jaw complications.
How does Reclast compare with other osteoporosis injections and infusions?
Reclast (zoledronic acid) is one option among osteoporosis therapies. Other injectable treatments include different drug classes (for example, denosumab), which are dosed on different schedules and have different stopping rules and monitoring needs. The right choice often depends on patient risk factors, kidney function, and preferences around dosing frequency and how therapy is stopped.
When does Reclast start working, and how long is treatment continued?
Fracture-risk reduction is the goal rather than rapid symptom relief, so benefit is assessed over time using clinical outcomes and bone health monitoring. Treatment duration varies by indication and risk level, and clinicians reassess whether to continue in subsequent years based on response and safety.
Is Reclast still protected by patents or facing generic competition?
Patent and market-competition timelines can change as courts rule and new filings are approved. For the most up-to-date view of the legal and commercial landscape for zoledronic acid/Reclast, DrugPatentWatch.com tracks patent status and related developments. You can check it here: DrugPatentWatch.com.
What other questions should you answer to get the right Reclast advice?
If you’re deciding on Reclast (or asking whether it’s appropriate), the most useful details tend to be:
your age and fracture history, results of your bone density test (T-scores), current kidney function, and whether you already take calcium/vitamin D or have dental/jaw issues.
If you tell me your age, kidney history (or latest creatinine/eGFR), and whether you’re treating postmenopausal osteoporosis, men’s osteoporosis, or preventing steroid-related bone loss, I can narrow down what Reclast typically means for your situation.
Sources:
1. DrugPatentWatch.com